SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Kroll Werner

(Last) (First) (Middle)
9975 SUMMERS RIDGE ROAD

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QUIDEL CORP /DE/ [ QDEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, R&D
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/27/2022 A 4,376(1) A $0.00 20,932 D
Common Stock 05/27/2022 F 2,170(2) D $103.45 18,762 D
Common Stock 05/27/2022 D(3) 18,762 D (3) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (4) 05/27/2022 M 4,376 (5) (5) Common Stock 4,376 $0.00 0 D
Non-Qualified Stock Options $46.41 05/27/2022 D(6) 2,303 (5) 01/16/2028 Common Stock 2,303 $0.00 0 D
Non-Qualified Stock Options $59.12 05/27/2022 D(6) 3,924 (7) 02/04/2029 Common Stock 3,924 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 3,925 (9) (9) Common Stock 3,925 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 2,743 (10) (10) Common Stock 2,743 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 823 (10) (10) Common Stock 823 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 4,268 (11) (11) Common Stock 4,268 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 1,962 (12) (12) Common Stock 1,962 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 2,625 (13) (13) Common Stock 2,625 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 3,510 (14) (14) Common Stock 3,510 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 10,642 (15) (15) Common Stock 10,642 $0.00 0 D
Restricted Stock Units (4) 05/27/2022 D(8) 7,256 (16) (16) Common Stock 7,256 $0.00 0 D
Explanation of Responses:
1. Reflects release of restricted stock units that were previously reported on a Form 4.
2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
3. Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
4. Each restricted stock unit represents the right to receive one share of Quidel common stock.
5. Vested in full.
6. Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
7. 5,888 shares are vested in full; 1,962 shares will vest on February 4, 2023.
8. Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
9. 3,925 shares will vest on February 4, 2023.
10. Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule.
11. 4,268 shares will vest on February 4, 2023.
12. 1,962 shares will vest in equal installments on July 1, 2022 and July 1, 2023.
13. 1,312 shares will vest on February 1, 2023; and 1,313 shares will vest on February 1, 2024.
14. 3,510 shares will vest in equal installments on July 28, 2022, July 28, 2023 and July 28, 2024.
15. 3,547 shares will vest on each of January 31, 2023 and January 31, 2024; 3,548 shares will vest on January 31, 2025.
16. 3,628 shares will vest on January 31, 2024; the remaining 3,628 shares will vest in equal installments on January 31, 2025 and January 31, 2026.
Remarks:
/s/ Phillip S. Askim, attorney-in-fact for Werner Kroll 06/01/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.